Abstract
Biomarkers become more and more important tools in clinical diagnosis of cutaneous malignancies. Furthermore, after vigorous validation, biomarkers may have influence on future prognostic classification systems. Clinical and histopathological parameters such as anatomic site, type of the primary tumor, tumor size, invasion depth, ulceration, vascular invasion, lymph node involvement and others are well established for their prognostic value. Additionally, an increasing variety of molecular markers have now been identified and described, providing a potential powerful platform for a more precise diagnosis and a more accurate prognostic sub-grouping of tumor entities. This might lead to future changes in existing classification systems, and might have consequences for the treatment and outcome of skin cancer patients. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. The aim of this report is to summarize the currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies malignant melanoma, squamous cell carcinoma, and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.
Keywords: Skin cancer, biomarker, prognosis, serum, immunohistochemistry
Current Cancer Therapy Reviews
Title: Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches
Volume: 4 Issue: 2
Author(s): Dirk Schadendorf, Jochen Utikal, Balwir Matharoo-Ball, Robert C. Rees and Selma Ugurel
Affiliation:
Keywords: Skin cancer, biomarker, prognosis, serum, immunohistochemistry
Abstract: Biomarkers become more and more important tools in clinical diagnosis of cutaneous malignancies. Furthermore, after vigorous validation, biomarkers may have influence on future prognostic classification systems. Clinical and histopathological parameters such as anatomic site, type of the primary tumor, tumor size, invasion depth, ulceration, vascular invasion, lymph node involvement and others are well established for their prognostic value. Additionally, an increasing variety of molecular markers have now been identified and described, providing a potential powerful platform for a more precise diagnosis and a more accurate prognostic sub-grouping of tumor entities. This might lead to future changes in existing classification systems, and might have consequences for the treatment and outcome of skin cancer patients. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. The aim of this report is to summarize the currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies malignant melanoma, squamous cell carcinoma, and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.
Export Options
About this article
Cite this article as:
Schadendorf Dirk, Utikal Jochen, Matharoo-Ball Balwir, Rees C. Robert and Ugurel Selma, Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310061
DOI https://dx.doi.org/10.2174/157339408784310061 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of COX-2 Inhibitors in Common Clinical Practice a Gastroenterologists Perspective
Current Topics in Medicinal Chemistry CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Cytotoxic and Chemopreventive Effects of Gemin D Against Different Mutagens Using In Vitro and In Vivo Assays
Anti-Cancer Agents in Medicinal Chemistry Potential Cell Signalling Mechanisms Involved in Differential Placental Angiogenesis in Mild and Severe Pre-Eclampsia
Current Vascular Pharmacology Novel Colchicine Derivatives and their Anti-cancer Activity
Current Topics in Medicinal Chemistry Salinomycin Suppresses Tumorigenicity of Liver Cancer Stem Cells and Wnt/Beta-catenin Signaling
Current Stem Cell Research & Therapy Inflammatory and Non-Inflammatory Roles for Toll-Like Receptors in Gastrointestinal Cancer
Current Pharmaceutical Design Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry Intracellular Proton Pumps as Targets in Chemotherapy: V-ATPases and Cancer
Current Pharmaceutical Design Biological Activity of Carotenoids: Its Implications in Cancer Risk and Prevention
Current Pharmaceutical Biotechnology Integrins: A Method of Early Intervention in the Treatment of Colorectal Liver Metastases
Current Pharmaceutical Design Fiber-Optic Technologies in Laser-Based Therapeutics: Threads for a Cure
Current Pharmaceutical Biotechnology Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets The Calcium-Sensing Receptor as a Regulator of Cellular Fate in Normal and Pathological Conditions
Current Molecular Medicine Editorial (Thematic Issue: Antiangiogenic Agents in the Management of Solid Malignancies)
Current Angiogenesis (Discontinued) Development of Linker-Conjugated Nanosize Lipid Vesicles: A Strategy for Cell Selective Treatment in Breast Cancer
Current Cancer Drug Targets Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews